AIMT - Aimmune Therapeutics Stock Trading

Aimmune (AIMT) has been on my 2019 watch list, but the stock's premium price prevented me from committing to a buy. Now, the recent sell-off has AIMT near the top of my shopping list. The company is in the process of launching their first FDA-approved product, Palforzia, for the mitigation of ...

Osmotica Pharmaceuticals (NASDAQ: OSMT ) initiated with Buy rating and $8 (74% upside) price target at SunTrust. More news on: Osmotica Pharmaceuticals plc, Epizyme, Inc., Baxter International Inc., Healthcare stocks news, Stocks on the move, , Read more ...

AcelRx Pharmaceuticals Reports Q4 Results, to Acquire Tetraphase Pharmaceuticals AcelRx ( ACRX ) reported its fourth quarter and full-year results while also announcing its plan to acquire Tetraphase Pharmaceuticals (TTPH). The company ended the year with $66.1 million in cash, cash equiva...